Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT03223220
PHASE2/PHASE3
Quelling of Excitotoxicity in Acute Stroke With Ketamine
Sponsor: Lower Merion Neurology Research Foundation
View on ClinicalTrials.gov
Summary
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-07-01
Completion Date
2027-12-31
Last Updated
2023-12-18
Healthy Volunteers
No
Conditions
Interventions
DRUG
Ketamine
IV infusion
OTHER
Normal Saline
IV infusion
DRUG
Midazolam injection
Injection
Locations (1)
Lankenau Medical Center
Wynnewood, Pennsylvania, United States